PDCD1 and neoplasm: Regarding pharmacodynamic markers, several authors have observed an increase in Ki-67+PD-1+ T cells, representative of a reinvigoration of exhausted lymphocytes, as well as an expansion of tumor-specific T cell clones, in the circulation of responders to ICIs (19–21).